AbbVie to acquire ImmunoGen to strengthen position in cancer therapies

Estimated read time 2 min read

A | a-+=

AbbVie, a global biopharmaceutical company, has announced a groundbreaking $10.1 billion acquisition of ImmunoGen, a move that underscores the increasing interest of major drugmakers in the burgeoning field of targeted cancer therapies. The deal positions AbbVie to capitalize on ImmunoGen’s innovative antibody drug conjugate (ADC) technology, particularly the promising cancer treatment Elahere.

Elahere has gained approval for ovarian cancer patients who have undergone previous therapies and is currently undergoing testing in earlier lines of treatment. As an ADC, Elahere belongs to a new class of cancer drugs characterized by a monoclonal antibody that precisely targets cancer cells, minimizing toxicity to healthy cells. The targeted nature of ADCs has sparked substantial interest from pharmaceutical companies, with Pfizer also making a significant move in this direction through its $43 billion acquisition of Seagen, a pioneer in antibody-drug conjugate treatments.

In the deal, AbbVie will pay $31.26 per share in cash for ImmunoGen, representing a substantial premium of 94.6% to the last closing price. Following the announcement, ImmunoGen’s shares experienced a remarkable surge of 90% in premarket trading, reaching $29.23. This surge is part of a broader trend for ImmunoGen, whose shares have more than tripled throughout the year, driven by positive results from a late-stage trial indicating that Elahere can extend the lives of patients.

For AbbVie, this strategic acquisition aligns with its broader plans to expand its presence in the competitive cancer drug market. The company faces intense competition in the United States for its top-selling product, Humira, a rheumatoid arthritis treatment. With the acquisition of ImmunoGen and its ADC technology, AbbVie aims to diversify its portfolio and reinforce its position in the rapidly evolving landscape of cancer therapies.

This move comes at a critical time for AbbVie, as its blockbuster blood cancer drug, Imbruvica, recently faced selection as one of the ten drugs subject to the first-ever price negotiations by U.S. Medicare insurance plans. These negotiations are anticipated to commence in 2026, adding an additional layer of complexity to AbbVie’s competitive landscape.

AbbVie’s acquisition of ImmunoGen marks a significant step towards solidifying its role as a key player in the field of targeted cancer therapies. The deal not only provides access to the promising Elahere but also reflects a broader industry trend as pharmaceutical giants strategically position themselves to meet the growing demand for innovative and effective cancer treatments.

(Source: WSJ | MarketWatch | CNBC | Fierce Pharma)

You May Also Like